Roeland E. Wasmann

University of Cape Town — South Africa

Medicine · Health Sciences

16h-index695citations59works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(19), Antibiotics Pharmacokinetics and Efficacy(13), Antifungal resistance and susceptibility(9), Tuberculosis Research and Epidemiology(8), Pharmacological Effects and Toxicity Studies(8)

Publications58 total

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated TB on BIC/FTC/TAF and Rifampicin
Clinical Infectious Diseases·2025Open Access
Fixed-dose combination bictegravir–emtricitabine–tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial
The Lancet HIV·2025· 1 citedOpen Access
Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV
Antimicrobial Agents and Chemotherapy·2025Open Access
A preliminary analysis of the impact of pharmacogenetic variation on bictegravir and dolutegravir concentrations in individuals with HIV and tuberculosis
British Journal of Clinical Pharmacology·2025Open Access
Brief Report: Pharmacokinetic Data of Atazanavir/Ritonavir in Second-Line Treatment of Children Living With HIV
JAIDS Journal of Acquired Immune Deficiency Syndromes·2025· 1 citedOpen Access
Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas
The Lancet Child & Adolescent Health·2025· 3 citedOpen Access
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling
CPT Pharmacometrics & Systems Pharmacology·2025· 10 citedOpen Access
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study
The Lancet HIV·2025· 2 cited
Weekly dihydroartemisinin–piperaquine versus monthly sulfadoxine–pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial
The Lancet Infectious Diseases·2024· 5 citedOpen Access
Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV
Journal of Antimicrobial Chemotherapy·2024· 4 citedOpen Access
Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial
Journal of the Pediatric Infectious Diseases Society·2024· 1 citedOpen Access
Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy
Antimicrobial Agents and Chemotherapy·2024· 2 citedOpen Access
Dose optimization of cefazolin in South African children undergoing cardiac surgery with cardiopulmonary bypass
CPT Pharmacometrics & Systems Pharmacology·2024Open Access
A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing
American Journal of Respiratory and Critical Care Medicine·2024· 18 citedOpen Access
Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa
British Journal of Clinical Pharmacology·2024· 4 citedOpen Access
Weekly Dihydroartemisinin-Piperaquine Versus Monthly Sulphadoxine-Pyrimethamine for Malaria  Chemoprevention in Children with Sickle Cell Anaemia in Uganda and Malawi: A Randomised, Double-Blind, Placebo-Controlled Trial (Chemcha)
SSRN Electronic Journal·2024· 2 citedOpen Access
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis
PLoS Medicine·2023· 7 citedOpen Access
Objectively measured medication adherence using assays for carvedilol and enalaprilat in patients with heart failure in Mozambique and Nigeria
International Journal of Cardiology Cardiovascular Risk and Prevention·2023· 4 citedOpen Access
A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing
2023Open Access
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial
Clinical Infectious Diseases·2023· 13 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Paolo Denti(27), Roger J. M. Brüggemann(15), Catherijne A. J. Knibbe(11), Lubbe Wiesner(11), Helen McIlleron(10), David M. Burger(8), Cornelis Smit(8), Diana M. Gibb(8), Aida N. Kawuma(8), Gary Maartens(8), Elin M. Svensson(7), Paul E. Verweij(6), Johan W. Mouton(6), Anneke C. Hesseling(6), Chishala Chabala(6), Phumla Sinxadi(6), Hylke Waalewijn(6), Eric P.A. van Dongen(5), Angela Colbers(5), Anna Turkova(5)